By Jason Derry —

Array BioPharma has
announced
that AstraZeneca has dosed a patient with its MEK
inhibitor, ARRY-704, in a Phase I clinical trial. By dosing the first patient, Array BioPharma
is now entitled to a $2 million milestone payment from AstraZeneca. ARRY-704 is an orally active MEK-inhibitor
with tumor suppressive activity.  Earlier
this week, Array BioPharma announced
that it has filed an Investigational New Drug (IND) application for ARRY-797, a p38
inhibitor, and plans to initiate Phase 1 clinical trials in cancer patients.